Results 211 to 220 of about 331,966 (252)

Comparative Real-World Efficacy of Anti-Vascular Endothelial Growth Factor Agents in Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Study.

Ophthalmologica
Berco E, Kozlov Y, Ostrovsky M, Tuli R, Kin Man Lee T, Samocha K, Shcolnik E, Goldfeather Ben Zaken S, Shoham-Hazon N.   +8 more
europepmc   +1 more source

Assessing Quality of Life and Patient-Reported Outcomes in Diabetic Macular Edema Treated With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Agents: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Shameem FJ, Asante Baadu F, Venugopal S, Iguh C, Hafiz MM, Zahid M, Azhar Uddin M.   +6 more
europepmc   +1 more source

Serologic parameters in young patients with retinal vein occlusion treated with anti-vascular endothelial growth factor. [PDF]

Int J Ophthalmol
Niu TT, Xiao Y, Lyu WJ, Zhou H.
europepmc   +1 more source

Anti-Vascular Endothelial Growth Factor Treatment Outcomes in Macular Telangiectasia: A Systematic Review.

Ophthalmologica
Sriranganathan A, Grad J, Mihalache A, Popovic MM, Kertes PJ, Kohly R, Muni RH.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy

Ophthalmic Surgery, Lasers and Imaging Retina, 2020
BACKGROUND AND OBJECTIVE: The purpose of this article is to review the role of anti-vascular endothelial growth factor (VEGF) therapy in treating patients with radiation retinopathy (RR). PATIENTS AND METHODS: RR can be associated with a significant decrease in visual acuity (VA ...
Nadim, Rayess, Prithvi, Mruthyunjaya
openaire   +2 more sources

Use of anti‐vascular endothelial growth factor in the management of pterygium

Acta Ophthalmologica, 2016
AbstractThe rising success of anti‐vascular endothelial growth factor (VEGF) therapies in ocular disease has stimulated the use of such treatments in the surgical management of pterygium. We reviewed the literature to better understand the safety and efficacy of the adjunctive role of anti‐VEGF treatments for pterygium excision.
Renata Kiri Mak, Tommy Chung Yan Chan, Marcus M Marcet, Bonnie Nga Kwan Choy, Jennifer Wei Huen Shum, Kendrick Co Shih, Ian Yat Hin Wong, Alex Lap Ki Ng   +7 more
openaire   +4 more sources

Anti-vascular endothelial growth factor and retinopathy of prematurity

British Journal of Ophthalmology, 2008
Retinopathy of prematurity1 (ROP) has been at the nexus of a progressive understanding of neovascularisation, in large part because of the mouse model of oxygen-induced retinopathy (OIR) developed by Lois Smith.2 This model has been very instructive, because it has crystallised the hypothesis that ROP in general is caused by a two-step or two-phase ...
openaire   +2 more sources

Anti-vascular endothelial growth factor agents for diabetic maculopathy

British Journal of Ophthalmology, 2009
The management of diabetic macular oedema is changing. The therapeutic armamentarium for diabetic macular oedema (DMO) includes a new group of drugs that inhibit vascular endothelial growth factor (VEGF). These anti-VEGF agents are already being used widely in DMO in clinical practice despite that several phase III trials on these drugs are still ...
A, Salam, J, DaCosta, S, Sivaprasad
openaire   +2 more sources

Anti‐vascular endothelial growth factor for myopic choroidal neovascularization

Clinical & Experimental Ophthalmology, 2012
AbstractMyopic choroidal neovascularization (CNV) is a vision‐threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle‐aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized‐controlled study in treatment of subfoveal myopic CNV.
Danny S, Ng, Alvin K H, Kwok, Clement W, Chan   +2 more
openaire   +2 more sources